NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial
Provided By PR Newswire
Last update: Aug 1, 2024
12-month data demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigation
Previous results showed PrimeC slowed disease progression by 36% and improved survival rates, highlighting its potential as a transformative ALS therapy
Read more at prnewswire.com
